Health Blueprint

Back to Longevity News

News summary

Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

Source: PR Newswire • Published: 02 Nov 2026, 14:30

Summarized by Masters of Longevity from PR Newswire.

FDA cleared Roche's cobas eplex RP3 to detect viral and bacterial respiratory targets.

Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
Key Takeaways
  • The RP3 panel detects up to 19 respiratory viral and bacterial targets.
  • Labs can choose up to five customizable panel configurations.
  • The automated sample-to-answer workflow delivers results in under two hours.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.